125 related articles for article (PubMed ID: 7499114)
1. A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.
Sosman JA; Flaherty LE; Liu PY; Fletcher W; Thompson JA; Hantel A; Sondak V
Invest New Drugs; 1995; 13(1):83-7. PubMed ID: 7499114
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.
Zalupski MM; Benedetti J; Balcerzak SP; Hutchins LF; Belt RJ; Hantel A; Goodwin JW
Invest New Drugs; 1993 Nov; 11(4):337-41. PubMed ID: 8157477
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group study.
Ravdin PM; Green S; Doroshow JH; Martino S
Invest New Drugs; 1994; 12(4):333-6. PubMed ID: 7775136
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of piroxantrone in gastric carcinoma. A Southwest Oncology Group study.
Hantel A; Tangen C; Gluck WL; Macdonald JS
Invest New Drugs; 1994; 12(2):159-61. PubMed ID: 7860236
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Jenkins TR; Tangen C; Macdonald JS; Weiss G; Chapman R; Hantel A
Invest New Drugs; 1993 Nov; 11(4):329-31. PubMed ID: 8157474
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy.
Ingle JN; Kuross SA; Mailliard JA; Loprinzi CL; Jung SH; Nelimark RA; Krook JE; Long HJ
Cancer; 1994 Sep; 74(6):1733-8. PubMed ID: 8082075
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.
Allen A; Wolf M; Crawford ED; Davis MP; Natale RB; Barnett ML
Invest New Drugs; 1992 Jul; 10(2):129-32. PubMed ID: 1500267
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group study 8918.
Malviya VK; Liu PY; Goldberg DA; Hantel A; O'Toole RV; Roach RW; Conrad ME; Alberts DS
Anticancer Drugs; 1996 Jul; 7(5):527-30. PubMed ID: 8862719
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.
Chang AY; Kim K; Glick J; Anderson T; Karp D; Johnson D
J Natl Cancer Inst; 1993 Mar; 85(5):388-94. PubMed ID: 8094467
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. A Southwest Oncology Group trial.
Taylor SA; Benedetti J; Schuller D; Richman SP; Broun GO; Hantel A
Invest New Drugs; 1993; 11(2-3):227-9. PubMed ID: 8262737
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
Albain KS; Liu PY; Hantel A; Poplin EA; O'Toole RV; Wade JL; Maddox AM; Alberts DS
Gynecol Oncol; 1995 Jun; 57(3):407-11. PubMed ID: 7774846
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of piroxantrone in metastatic gastric adenocarcinoma.
Pazdur R; Bready B; Scalzo AJ; Brandof JE; Close DR; Kolbye S; Winn RJ
Invest New Drugs; 1994; 12(3):263-5. PubMed ID: 7896547
[TBL] [Abstract][Full Text] [Related]
13. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
Slavik M; Liu PY; Kraut EH; Natale RB; Flaherty LE; Sondak VK
Invest New Drugs; 1995; 13(2):143-7. PubMed ID: 8617577
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of piroxantrone in advanced squamous cell carcinoma of the cervix: a Gynecological Oncology Group study.
Lincoln S; Blessing JA; McGehee R; Lentz SS
Am J Clin Oncol; 1997 Feb; 20(1):84-5. PubMed ID: 9020296
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ
Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor.
Savarese DM; Denicoff AM; Berg SL; Hillig M; Baker SP; O'Shaughnessy JA; Chow C; Otterson GA; Balis FM; Poplack DG
J Clin Oncol; 1993 Sep; 11(9):1795-803. PubMed ID: 7689093
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
Whitehead RP; Unger JM; Flaherty LE; Eckardt JR; Taylor SA; Didolkar MS; Samlowski W; Sondak VK
Invest New Drugs; 2001; 19(3):239-43. PubMed ID: 11561681
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Arseneau JC; Schoenfeld DA; Borden EC
Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
